This document is an excerpt from the EUR-Lex website
Document 32016R1904
Commission Delegated Regulation (EU) 2016/1904 of 14 July 2016 supplementing Regulation (EU) No 1286/2014 of the European Parliament and of the Council with regard to product intervention (Text with EEA relevance)
Commission Delegated Regulation (EU) 2016/1904 of 14 July 2016 supplementing Regulation (EU) No 1286/2014 of the European Parliament and of the Council with regard to product intervention (Text with EEA relevance)
Commission Delegated Regulation (EU) 2016/1904 of 14 July 2016 supplementing Regulation (EU) No 1286/2014 of the European Parliament and of the Council with regard to product intervention (Text with EEA relevance)
C/2016/4369
OJ L 295, , pp. 11–18
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
In force
|
29.10.2016 |
EN |
Official Journal of the European Union |
L 295/11 |
COMMISSION DELEGATED REGULATION (EU) 2016/1904
of 14 July 2016
supplementing Regulation (EU) No 1286/2014 of the European Parliament and of the Council with regard to product intervention
(Text with EEA relevance)
THE EUROPEAN COMMISSION,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to Regulation (EU) No 1286/2014 of the European Parliament and of the Council of 26 November 2014 on key information documents for packaged retail and insurance-based investment products (PRIIPs) (1) and in particular Article 16(8) and Article 17(7) thereof,
Whereas:
|
(1) |
This Regulation specifies certain aspects of the intervention powers granted to competent authorities and, in exceptional circumstances, the European Insurance and Occupational Pensions Authority (EIOPA) established and exercising its powers in accordance with Regulation (EU) No 1094/2010 of the European Parliament and of the Council (2), as regards the criteria and factors to be taken into account for determining the existence of a significant investor protection concern or threat to the orderly functioning and integrity of financial markets or to the stability of the whole or part of the financial system of at least one Member State or respectively of the Union. |
|
(2) |
A list of criteria and factors to be taken into account by competent authorities and EIOPA when determining such a concern or threat should be established to ensure a consistent approach while permitting appropriate action to be taken where unforeseen adverse events or developments occur. The existence of a ‘threat’, one of the prerequisites of the intervention in the perspective of the orderly functioning and integrity of financial or commodity markets or stability of the financial system, requires a higher threshold than the existence of a ‘significant concern’, which is the prerequisite of the intervention for investor protection. The need to assess all criteria and factors that could be present in a specific situation should not, however, prevent the temporary intervention power from being used by competent authorities and EIOPA where only one of the factors or criteria leads to such a concern or threat. |
|
(3) |
The provisions in this Regulation are closely linked, since they deal with the product intervention powers vested in both the national competent authorities and EIOPA. To ensure coherence between those provisions which should enter into force at the same time, and in order to facilitate a comprehensive view for stakeholders and, in particular, for EIOPA and competent authorities exercising the intervention powers, it is necessary to include these provisions in a single Regulation, |
HAS ADOPTED THIS REGULATION:
Article 1
Criteria and factors for the purposes of EIOPA temporary product intervention powers
(Article 16(2) of Regulation (EU) No 1286/2014)
1. For the purposes of Article 16(2) of Regulation (EU) No 1286/2014, EIOPA shall assess the relevance of all factors and criteria listed in paragraph 2, and consider all relevant factors and criteria in determining when the marketing, distribution or sale of certain insurance-based investment products or a type of financial activity or practice creates a significant investor protection concern or a threat to the orderly functioning and integrity of financial markets or to the stability of the whole or part of the financial system of the Union.
For the purpose of the first subparagraph, EIOPA may determine the existence of a significant investor protection concern or a threat to the orderly functioning and integrity of financial markets or to the stability of whole or part of the financial system of the Union based on one or more of those factors or criteria.
2. The factors and criteria to be assessed by EIOPA to determine whether there is a significant investor protection concern or a threat to the orderly functioning and integrity of financial markets or to the stability of whole or part of the financial system of the Union shall be the following:
|
(a) |
the degree of complexity of the insurance-based investment product or type of financial activity or practice of an insurance or reinsurance undertaking, taking into account, in particular:
|
|
(b) |
the size of potential detrimental consequences, considering in particular:
|
|
(c) |
the type of investors involved in a financial activity or financial practice or to whom an insurance-based investment product is marketed or sold, taking into account, in particular:
|
|
(d) |
the degree of transparency of the insurance-based investment product or type of activity or practice, taking into account, in particular:
|
|
(e) |
the particular characteristics or underlying assets of the insurance-based investment product, financial activity or financial practice, including any embedded leverage, taking into account, in particular:
|
|
(f) |
the existence and degree of disparity between the expected return or profit for investors and the risk of loss in relation to the insurance-based investment product, financial activity or financial practice, taking into account, in particular:
|
|
(g) |
the ease and cost with which investors are able to sell the relevant insurance-based investment product or to switch to another product, taking into account, in particular:
|
|
(h) |
the pricing and associated costs of insurance-based investment product, financial activity or financial practice, taking into account, in particular:
|
|
(i) |
the degree of innovation of an insurance-based investment product, a financial activity or a financial practice, taking into account in particular:
|
|
(j) |
the selling practices associated with the insurance-based investment product, taking into account, in particular:
|
|
(k) |
the financial and business situation of the issuer of an insurance-based investment product, taking into account, in particular:
|
|
(l) |
whether the underlying assets of the insurance-based investment product or financial activities or financial practice pose a high risk to the performance of transactions entered into by participants or investors in the relevant market; |
|
(m) |
whether the characteristics of an insurance-based investment product make it particularly susceptible to being used for the purposes of financial crime, in particular whether those characteristics could potentially encourage the use of the insurance-based investment products for:
|
|
(n) |
whether the financial activity or financial practice poses a particularly high risk to the resilience or smooth operation of markets; |
|
(o) |
whether an insurance-based investment product, financial activity or financial practice could lead to a significant and artificial disparity between prices of a derivative and those in the underlying market; |
|
(p) |
whether an insurance-based investment product, financial practice or financial activity poses a high risk to the market or payment systems infrastructure, including trading, clearing and settlement systems; |
|
(q) |
whether an insurance-based investment product, financial activity or financial practice may threaten investors' confidence in the financial system; or |
|
(r) |
whether the insurance-based investment product, financial practice or financial activity poses a high risk of disruption to financial institutions deemed to be important to the financial system of the Union. |
Article 2
Criteria and factors to be taken into account by competent authorities for the purposes of insurance-based investment product intervention powers
(Article 17(2) of Regulation (EU) No 1286/2014)
1. For the purposes of Article 17(2) of Regulation (EU) No 1286/2014, competent authorities shall assess the relevance of all factors and criteria listed in paragraph 2, and take into consideration all relevant factor(s) and criteria in determining when the marketing, distribution or sale of certain insurance-based investment products or a type of financial activity or practice creates a significant investor protection concern or a threat to the orderly functioning and integrity of financial markets or to the stability of the whole or part of the financial system within at least one Member State.
For the purposes of the first subparagraph, competent authorities may determine the existence of a significant investor protection concern or a threat to the orderly functioning and integrity of financial markets or to the stability of whole or part of the financial system within at least one Member State based on one or more of those factors and criteria.
2. The factors and criteria to be assessed by competent authorities to determine whether there is a significant investor protection concern or a threat to the orderly functioning and integrity of financial markets or to the stability of whole or part of the financial system within at least one Member State shall include the following:
|
(a) |
the degree of complexity of the insurance-based investment product or type of financial activity or practice of an insurance or reinsurance undertaking, taking into account, in particular:
|
|
(b) |
the size of potential detrimental consequences, considering in particular:
|
|
(c) |
the type of investors involved in a financial activity or financial practice or to whom an insurance-based investment product is marketed or sold, taking into account, in particular:
|
|
(d) |
the degree of transparency of the insurance-based investment product or type of activity or practice, taking into account, in particular:
|
|
(e) |
the particular characteristics or underlying assets of the insurance-based investment product financial activity or financial practice, including any embedded leverage taking into account, in particular:
|
|
(f) |
the existence and degree of disparity between the expected return or profit for investors and the risk of loss in relation to the insurance-based investment product, financial activity or financial practice, taking into account in particular:
|
|
(g) |
the ease and cost with which investors are able to sell the relevant insurance-based investment product or to switch to another product, taking into account in particular:
|
|
(h) |
the pricing and associated costs of insurance-based investment product, financial activity or financial practice, taking into account’ in particular:
|
|
(i) |
the degree of innovation of an insurance-based investment product, a financial activity or a financial practice, taking into account in particular:
|
|
(j) |
the selling practices associated with the insurance-based investment product, taking into account in particular:
|
|
(k) |
the financial and business situation of the issuer of an insurance-based investment product, taking into account in particular:
|
|
(l) |
whether the underlying assets of the insurance-based investment product or financial activities or financial practice pose a high risk to the performance of transactions entered into by participants or investors in the relevant market; |
|
(m) |
whether the characteristics of an insurance-based investment product make it particularly susceptible to being used for the purposes of financial crime, in particular whether those characteristics could potentially encourage the use of the insurance-based investment products for:
|
|
(n) |
whether the financial activity or financial practice poses a particularly high risk to the resilience or smooth operation of markets; |
|
(o) |
whether an insurance-based investment product, financial activity or financial practice could lead to a significant and artificial disparity between prices of a derivative and those in the underlying market; |
|
(p) |
whether an insurance-based investment product, financial practice or financial activity poses a risk to the market or payment systems infrastructure, including trading, clearing and settlement systems; |
|
(q) |
whether an insurance-based investment product, financial activity or financial practice may threaten investors' confidence in the financial system; or |
|
(r) |
whether the insurance-based investment product, financial practice or financial activity poses a high risk of disruption to financial institutions deemed to be important to the financial system of the Member State of the relevant competent authority. |
Article 3
Entry into force
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
It shall apply from 31 December 2016.
This Regulation shall be binding in its entirety and directly applicable in all Member States.
Done at Brussels, 14 July 2016.
For the Commission
The President
Jean-Claude JUNCKER
(1) OJ L 352, 9.12.2014, p. 1.
(2) Regulation (EU) No 1094/2010 of the European Parliament and of the Council of 24 November 2010 establishing a European Supervisory Authority (European Insurance and Occupational Pensions Authority), amending Decision No 716/2009/EC and repealing Commission Decision 2009/79/EC (OJ L 331, 15.12.2010, p. 48).
(3) Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (OJ L 173, 12.6.2014, p. 349).